Zydus Lifesciences receives USFDA approval to produce prostrate cancer drug ...Middle East

Zydus Lifesciences on Wednesday said it has received approval from the US health regulator to produce a generic prostate cancer treatment drug. The company has received tentative approval from the US Food and Drug Administration (USFDA) to manufacture Enzalutamide tablets (40 mg and 80 mg), the drug maker said in a regulatory filing. Enzalutamide tablets are androgen receptor inhibitors indicated for the treatment of patients with castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer. The product would be manufactured at the Group's manufacturing site at SEZ, Ahmedabad. As per IQVIA MAT July 2024 data, Enzalutamide tablets (40 mg and 80 mg) had annual sales

Read More Details
Finally We wish PressBee provided you with enough information of ( Zydus Lifesciences receives USFDA approval to produce prostrate cancer drug )

Also on site :

• 11 Eastern Europeans charged in $10.6 billion Medicare fraud scheme
• China's industrial profits plunge 9.1%, steepest fall in seven months
• Cangzhou Blends Dual UNESCO Heritage with Innovation to Drive Next-Generation Tourism